Interpace Biosciences Inc (IDXG) NPV
Interpace Biosciences, Inc. enables precision medicine principally in oncology by offering specialized services along the therapeutic value chain from early diagnosis and prognostic planning to targeted therapeutic applications through its clinical and pharma services. The Company’s clinical services provide clinically useful molecular diagnostic tests, bioinformatics and pathology services for evaluating the risk of cancer in personalized medicine for improved patient diagnosis and management. Through its pharma services, it develops, commercializes and provides molecular and biomarker-based tests and services. Its pharma services provide pharmacogenomics testing, genotyping, biorepository and other specialized services to the pharmaceutical and biotech industries and advance personalized medicine. The Company has five commercialized molecular diagnostic tests in the marketplace, which include PancraGEN, PanDNA, ThyGeNEXT, ThyraMIR and RespriDx. Its pipeline product includes BarreGEN.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.